Analysis of the QTc Interval During Olanzapine Treatment of Patients With Schizophrenia and Related Psychosis
J Clin Psychiatry 2001;62:191-198
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: There may be a temporal association
between some antipsychotics and prolongation of the
heart-rate-corrected QT interval (QTc) representing a delay in
ventricular repolarization. QTc prolongation significantly
exceeding normal intraindividual and interindividual variation
may increase the risk of ventricular tachydysrhythmias,
especially torsade de pointes, and therefore, sudden cardiac
Method: Electrocardiogram recordings obtained as
part of the safety assessment of olanzapine in 4 controlled,
randomized clinical trials (N = 2700) were analyzed. These
analyses were conducted to characterize any change in QTc
temporally associated with olanzapine, compared with placebo,
haloperidol, and risperidone, in acutely psychotic patients
(DSM-III-R and DSM-IV) and to characterize variability and
temporal course of the QTc in this patient population. Changes
from baseline to minimum and maximum QTc were tested for
significance, and baseline to acute-phase endpoint change in mean
QTc was tested for significance within treatments and for
differences between olanzapine and comparators. The possibility
of a linear relationship between dose of olanzapine and mean
change in QTc, as well as incidence of treatment-emergent
prolongation of QTc (change from < 430 msec at baseline to
>= 430 msec at endpoint), was tested.
Results: The incidence of maximum QTc >= 450
msec during treatment was approximately equal to the incidence of
QTc >= 450 msec at baseline.
Conclusion: Results of these analyses suggest
that olanzapine, as therapeutically administered to patients with
schizophrenia and related psychoses, does not contribute to QTc
prolongation resulting in potentially fatal ventricular